Morphic Holding, Inc. (NASDAQ:MORF) Stock Position Lifted by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. increased its position in shares of Morphic Holding, Inc. (NASDAQ:MORF) by 88.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 635,064 shares of the company’s stock after purchasing an additional 297,567 shares during the period. Goldman Sachs Group Inc. owned 1.27% of Morphic worth $18,341,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Point72 Asset Management L.P. increased its stake in Morphic by 83.3% in the 4th quarter. Point72 Asset Management L.P. now owns 4,591,000 shares of the company’s stock worth $132,588,000 after purchasing an additional 2,086,617 shares in the last quarter. Wellington Management Group LLP lifted its stake in Morphic by 48.5% in the 3rd quarter. Wellington Management Group LLP now owns 3,421,820 shares of the company’s stock worth $78,394,000 after acquiring an additional 1,117,985 shares in the last quarter. Vanguard Group Inc. lifted its stake in Morphic by 10.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,107,410 shares of the company’s stock worth $48,281,000 after acquiring an additional 200,772 shares in the last quarter. Federated Hermes Inc. grew its stake in Morphic by 13.1% during the 4th quarter. Federated Hermes Inc. now owns 1,000,000 shares of the company’s stock valued at $28,880,000 after acquiring an additional 115,975 shares in the last quarter. Finally, Jennison Associates LLC acquired a new position in shares of Morphic in the 4th quarter valued at about $17,818,000. Institutional investors own 94.25% of the company’s stock.

Morphic Stock Performance

Shares of MORF opened at $34.01 on Friday. The company has a market capitalization of $1.70 billion, a PE ratio of -9.72 and a beta of 1.49. The company’s 50 day moving average price is $29.27 and its 200 day moving average price is $31.23. Morphic Holding, Inc. has a 52 week low of $19.34 and a 52 week high of $62.08.

Morphic (NASDAQ:MORF) last released its quarterly earnings data on Thursday, April 25th. The company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.05. On average, equities analysts forecast that Morphic Holding, Inc. will post -4.07 earnings per share for the current fiscal year.

Morphic Profile

Morphic Holding, Inc, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease.